Analysis Of A Cystic Fibrosis-Specific Antibiogram Before And After Fda Approval Of Elexacaftor/Tezacaftor/Ivacaftor (ETI)

Authors

Kathryn Bohannan, Children's Mercy Kansas CityFollow
Claire Elson, Children's Mercy HospitalFollow
Jane Beyer, Children's Mercy Kansas City

Files

Publication Date

5-2022

Abstract

The highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (ETI) was FDA approved in 2019. Yearly cystic fibrosis-specific antibiograms at Children’s Mercy – Kansas City were analyzed pre-ETI approval (2018-2019) and post-ETI approval (2020-2021) to evaluate differences in susceptibility to antibiotics and the prevalence of selected microorganisms.

Notes

Poster not submitted.

Document Type

Poster

Recommended Citation

Bohannan, Kathryn; Elson, Claire; and Beyer, Jane, "Analysis Of A Cystic Fibrosis-Specific Antibiogram Before And After Fda Approval Of Elexacaftor/Tezacaftor/Ivacaftor (ETI)" (2022). Research at Children's Mercy Month 2022. 33.
https://scholarlyexchange.childrensmercy.org/research_month2022/33